HERTFORDSHIRE, England and PITTSBURGH, Oct. 26, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United Kingdom's High Court of Justice has issued a decision in favor of Mylan and its European partner Synthon, finding all claims of Teva's patent EP (UK) 2 949 335 (EP 335) relating to Copaxone® 40 mg/mL invalid based on obviousness. www.KatalystHLS.com
http://newsroom.mylan.com/2017-10-26-Mylan-Wins-UK-Court-Ruling-Related-to-Copaxone-R-40-mg-mL-Patent
No comments:
Post a Comment